Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Agent Targeted Therapies in Advanced NSCLC
NCT02276027Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2015
- Primary completion
- Oct 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of Luminespib, alpelisib, capmatinib, ceritinib, binimetinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Jan 2015; status: completed.
02
Drugs
Luminespibalpelisibcapmatinibceritinibbinimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02276027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02276027.